RDInvesting Provides Investors with Free In-Depth Equity Reports on AMSG, IR, TNDM and XONEadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Amsurg Corp. (NASDAQ: AMSG) shares gained 0.22 percent to close at $46.16 a share Monday. The stock traded between $45.82 and $46.72 on volume of 161,697 shares traded. Analysts at Sidoti have recently initiated coverage on the company with a “neutral” rating and a price target of $48.00. Shares of Amsurg have gained approximately 53.0 percent year-to-date.
Find out more about Amsurg including full access to the free equity report at:
Ingersoll-Rand PLC (NYSE: IR) shares gained 0.21 percent to close at $56.81 a share Monday. The stock traded between $55.73 and $56.99 on volume of 2.47 million shares traded. Analysts at MKM Partners have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Ingersoll-Rand have gained approximately 18.0 percent year-to-date.
Find out more about Ingersoll-Rand including full access to the free equity report at:
Tandem Diabetes Care Inc. (NASDAQ: TNDM) shares declined 3.55 percent to close at $23.91 a share Monday. The stock traded between $23.40 and $25.04 on volume of 240,508 shares traded. Bank of America analyst Bob Hopkins has recently initiated coverage on the company with a “neutral” rating and a price target of $27.00.
Find out more about Tandem Diabetes Care including full access to the free equity report at:
ExOne Co. (NASDAQ: XONE) shares declined 3.46 percent to close at $53.60 a share Monday. The stock traded between $53.50 and $55.95 on volume of 323,406 shares traded. Analysts at Pacific Crest have recently initiated coverage on the company with a “sector perform” rating. Shares of ExOne have gained approximately 100.0 percent year-to-date.
Find out more about ExOne including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: December 10th, 2013 under ACCESSWIRE.